Show simple item record

dc.contributor.authorSmrke, A
dc.contributor.authorAnderson, PM
dc.contributor.authorGulia, A
dc.contributor.authorGennatas, S
dc.contributor.authorHuang, PH
dc.contributor.authorJones, RL
dc.date.accessioned2021-01-22T15:53:42Z
dc.date.issued2021-01-15
dc.identifier.citationCells, 2021, 10 (1)
dc.identifier.issn2073-4409
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4310
dc.identifier.eissn2073-4409
dc.identifier.doi10.3390/cells10010172
dc.description.abstractOsteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd-3rd decades of life. Response to the aggressive and highly toxic neoadjuvant methotrexate-doxorubicin-cisplatin (MAP) chemotherapy schedule is strongly predictive of outcome. Outcomes for patients with osteosarcoma have not significantly changed for over thirty years. There is a need for more effective treatment for patients with high risk features but also reduced treatment-related toxicity for all patients. Predictive biomarkers are needed to help inform clinicians to de-escalate or add therapy, including immune therapies, and to contribute to future clinical trial designs. Here, we review a variety of approaches to improve outcomes and quality of life for patients with osteosarcoma with a focus on incorporating toxicity reduction, immune therapy and molecular analysis to provide the most effective and least toxic osteosarcoma therapy.
dc.formatElectronic
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleFuture Directions in the Treatment of Osteosarcoma.
dc.typeJournal Article
dcterms.dateAccepted2021-01-13
rioxxterms.versionofrecord10.3390/cells10010172
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2021-01-15
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCells
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.publication-statusPublished
pubs.volume10
pubs.embargo.termsNot known
icr.researchteamMolecular and Systems Oncologyen_US
dc.contributor.icrauthorHuang, Paulen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0